Status:
COMPLETED
An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atheroscleroti...
Eligibility Criteria
Inclusion
- Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age greater than or equal to 18 years at the time of signing informed consent.
- Diagnosed with T2D grater than or equal to 180 days prior to the day of signing informed consent
Exclusion
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Mental incapacity, unwillingness, inability, or language barriers precluding adequate understanding or cooperation
- Diagnosed with Type 1 Diabetes (T1D).
- Patients with known congenital heart disease/malformation
Key Trial Info
Start Date :
April 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
4089 Patients enrolled
Trial Details
Trial ID
NCT05317845
Start Date
April 21 2022
End Date
August 31 2022
Last Update
March 28 2023
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Manama, Bahrain
2
Novo Nordisk Investigational Site
Alexandria, Egypt
3
Novo Nordisk Investigational Site
Amman, Jordan
4
Novo Nordisk Investigational Site
As Sālimīyah, Kuwait